Pennsylvania
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Pennsylvania: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Pennsylvania adheres to similar principles established by the Supreme Court in Myriad, particularly regarding the patentability of naturally occurring products and the standards for what constitutes a 'new invention.' This aligns with the state's commitment to promoting innovation while protecting public access to fundamental genetic information.
In Pennsylvania, naturally occurring genetic sequences cannot be patented unless significantly altered by human intervention to create a new and useful application.
The court held that claims to isolated DNA sequences failed to satisfy the requirements of patentability as they did not constitute a 'new composition of matter.'
This case adjudicated the applicability of patent principles to public health, affirming that public access to genetic materials is paramount and not subject to proprietary claims.
The court determined that in order to patent a genetic invention, significant modification must be demonstrated to enhance its utility beyond natural functions.
While federal patent law under the Supreme Court's ruling in Myriad provides a broad framework prohibiting the patenting of naturally occurring genetic sequences, Pennsylvania law underscores the public interest in access to genetic materials. Pennsylvania's decisions often reflect state priorities in health and innovation, which can lead to more restrictive interpretations compared to federal standards.
Understanding the implications of Myriad in Pennsylvania is critical, as issues involving the patentability of biological materials may appear on the Pennsylvania bar exam, particularly in the context of intellectual property law.